How do I transition a patient from risperidone oral to paliperidone palmitate (Invega Sustenna) long-acting injectable (LAI)?

When transitioning a patient from risperidone oral to paliperidone palmitate (Invega Sustenna), information on the manufacturer’s current website states that all patients transitioning from oral antipsychotics must follow the recommended initiation dosing of 234 mg (day 1), 156 mg (day 8), both administered in the deltoid muscle. No oral supplementation is required.

The paliperidone palmitate label does not specifically address conversion of risperidone tablets to paliperidone palmitate. Additional information on the manufacturer’s website estimates that each risperidone 1 mg is equivalent to paliperidone palmitate 39 mg. The patient’s third injection will be at the maintenance dose designated by their clinician, either 117 mg, 156 mg, or 234 mg.

Paliperidone is OH-risperidone, the active metabolite of risperidone, which explains the drugs’ similarities, as well as ability to establish tolerance by using either oral risperidone or paliperidone.


FDA medication label

Information on this topic is found in the FDA medication label. Here is the most recent label, at time of writing. Medication labels can be found by searching Drugs@FDA at the FDA website. Labels are also available using the Drugs@FDA app for Apple or Android devices. Labels change over time, and the current label should always be consulted.

If you would like more information on this topic, or would like to provide any feedback, please send us a message using our consultation system. Be sure to let us know about which tip you are writing. We would love to hear from you, and the consultation system is free to use and confidential. Thank you!
  • Was this Helpful ?
  • YesNo

Join our #MissionForBetter now

Sign up for our newsletter. We’ll let you know about new resources, education, and more.

Saved Posts